Author:
Ittershagen Stacie,Ericson Solveig,Eldjerou Lamis,Shojaee Ali,Bleickardt Eric,Patel Manisha,Taran Tetiana,Anak Oezlem,Hall Charlene,Leung Mimi,Roccoberton Deborah,Salmon Florence,Fuchs Miriam,Romanov Vadim,Lebwohl David
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Reference32 articles.
1. Kymriah (tisagenlecleucel) suspension for intravenous infusion [package insert]. East Hanover, NJ: Novartis Pharmceuticals Corporation; 2018.
2. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–33.
https://doi.org/10.1056/NEJMoa1103849
.
3. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.
https://doi.org/10.1126/scitranslmed.3002842
.
4. June CH. Chimeric antigen receptors: engineering designer T cells for cancer therapy. Presented at: 2012 American Society of Clinical Oncology annual meeting, June 5, 2012; Chicago, IL. Available at:
https://meetinglibrary.asco.org/record/68679/video
. Accessed November 7, 2018.
5. Penn Medicine. University of Pennsylvania and Novartis form Alliance to expand use of personalized T cell therapy for Cancer patients [press release]. Available at:
https://www.pennmedicine.org/news/news-releases/2012/august/university-of-pennsylvania-and
. Accessed November 7, 2018. Philadelphia, PA: Penn Medicine; 2012.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献